LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

LLY

1,057.51

+1.46%↑

JNJ

208.35

-1.04%↓

ABBV

222.91

-0.6%↓

UNH

328.46

-0.81%↓

AZN

90.63

+0.8%↑

Search

Owens & Minor Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

3.16 2.93

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.08

Max

3.27

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-66M

-150M

Pardavimai

15M

697M

Pelnas, tenkantis vienai akcijai

0.25

Pelno marža

-21.552

Darbuotojai

23,200

EBITDA

129M

89M

Rekomendacijos

By TipRanks

Rekomendacijos

Parduoti

12 mėnesių prognozė

+57.56% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-190M

233M

Ankstesnė atidarymo kaina

0.23

Ankstesnė uždarymo kaina

3.16

Naujienos nuotaikos

By Acuity

50%

50%

167 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Owens & Minor Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-18 23:54; UTC

Karštos akcijos

Stocks to Watch: Nike, Cassava Sciences, KB Home

2025-12-18 23:51; UTC

Uždarbis

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

2025-12-18 23:39; UTC

Pagrindinės rinkos jėgos

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

2025-12-18 22:57; UTC

Įsigijimai, susijungimai, perėmimai

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

2025-12-18 21:40; UTC

Uždarbis

Nike Sales Tick Up, But China Weakness Persists

2025-12-18 23:45; UTC

Rinkos pokalbiai

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

2025-12-18 23:37; UTC

Rinkos pokalbiai
Uždarbis

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

2025-12-18 23:36; UTC

Rinkos pokalbiai

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

2025-12-18 23:03; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

2025-12-18 23:02; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

2025-12-18 23:00; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

2025-12-18 22:59; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

2025-12-18 22:58; UTC

Įsigijimai, susijungimai, perėmimai

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

2025-12-18 22:57; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

2025-12-18 22:56; UTC

Įsigijimai, susijungimai, perėmimai

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

2025-12-18 22:55; UTC

Uždarbis

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

2025-12-18 21:59; UTC

Uždarbis

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

2025-12-18 21:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-12-18 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-18 21:35; UTC

Uždarbis

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

2025-12-18 21:31; UTC

Uždarbis

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Greater China Rev Down 17% >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q EPS 53c >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Apparel Rev $3.91B >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Equipment Rev $550M >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q N Amer Rev $5.63B >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Footwear Rev $7.66B >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

2025-12-18 21:15; UTC

Uždarbis

Nike 2Q Greater China Rev $1.42B >NKE

Akcijų palyginimas

Kainos pokytis

Owens & Minor Inc Prognozė

Kainos tikslas

By TipRanks

57.56% į viršų

12 mėnesių prognozė

Vidutinis 4.9 USD  57.56%

Aukščiausias 6 USD

Žemiausias 4 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Owens & Minor Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Parduoti

3 ratings

0

Pirkti

2

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

6.98 / 7.075Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

167 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Owens & Minor Inc

Owens & Minor, Inc., together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates through Products & Healthcare Services and Patient Direct segments. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes branded products and its proprietary products. This segment also offers services to healthcare providers, including supplier management, analytics, inventory management, and clinical supply management; and various programs to provide outsourced logistics and marketing solutions to its suppliers. The Patient Direct segment provides products and services for in-home care and delivery across diabetes treatment, home respiratory therapy, and obstructive sleep apnea treatment. This segment supplies a range of other home medical equipment, patient care products, including ostomy, wound care, urology, incontinence and other products and services. It serves multi-facility networks of healthcare providers, independent hospitals, surgery centers, physicians' practices, and networks of hospitals directly, as well as indirectly through third-party distributors. Owens & Minor, Inc. was founded in 1882 and is headquartered in Mechanicsville, Virginia.
help-icon Live chat